Search Results - "Nitz, Ulrike"

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment by Gluz, Oleg, Nitz, Ulrike A, Christgen, Matthias, Kates, Ronald E, Shak, Steven, Clemens, Michael, Kraemer, Stefan, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Kusche, Manfred, Heyl, Volker, Lorenz-Salehi, Fatemeh, Just, Marianne, Hofmann, Daniel, Degenhardt, Tom, Liedtke, Cornelia, Svedman, Christer, Wuerstlein, Rachel, Kreipe, Hans H, Harbeck, Nadia

“…The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool in early hormone receptor-positive breast cancer (BC); however, only a few…”
Get full text

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer by Nitz, Ulrike A., Gluz, Oleg, Kümmel, Sherko, Christgen, Matthias, Braun, Michael, Aktas, Bahriye, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Darsow, Maren, Krauss, Katja, Nuding, Benno, Thill, Marc, Potenberg, Jochem, Uleer, Christoph, Warm, Mathias, Fischer, Hans Holger, Malter, Wolfram, Hauptmann, Michael, Kates, Ronald E., Gräser, Monika, Würstlein, Rachel, Shak, Steven, Baehner, Frederick, Kreipe, Hans H., Harbeck, Nadia

“…PURPOSE To our knowledge, WSG-ADAPT-HR+/HER2– (ClinicalTrials.gov identifier: NCT01779206 ; n = 5,625 registered) is the first trial combining the 21-gene…”
Get full text

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial by Kolberg-Liedtke, Cornelia, Gluz, Oleg, Heinisch, Fred, Feuerhake, Friedrich, Kreipe, Hans, Clemens, Michael, Nuding, Benno, Malter, Wolfram, Reimer, Toralf, Wuerstlein, Rachel, Graeser, Monika, Shak, Steve, Nitz, Ulrike, Kates, Ronald, Christgen, Matthias, Harbeck, Nadia

“…The presence of tumor-infiltrating lymphocytes has been associated with prognosis and chemotherapy response, particularly in high-risk breast cancer subtypes…”
Get full text

Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients by Fischer, Johannes C., Niederacher, Dieter, Topp, Stefan A., Honisch, Ellen, Schumacher, Sarah, Schmitz, Norma, Föhrding, Luisa Zacarias, Vay, Christian, Hoffmann, Imke, Kasprowicz, Nikola S., Hepp, Philip G., Mohrmann, Svjetlana, Nitz, Ulrike, Stresemann, Antje, Krahn, Thomas, Henze, Tanja, Griebsch, Evelyn, Raba, Katharina, Rox, Jutta M., Wenzel, Folker, Sproll, Christoph, Janni, Wolfgang, Fehm, Tanja, Klein, Christoph A., Knoefel, Wolfram Trudo, Stoecklein, Nikolas H.

“…Circulating tumor cells (CTCs) are promising biomarkers for diagnosis and therapy in systemic cancer. However, their infrequent and unreliable detection,…”
Get full text

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial by Harbeck, Nadia, Nitz, Ulrike A, Christgen, Matthias, Kümmel, Sherko, Braun, Michael, Schumacher, Claudia, Potenberg, Jochem, Tio, Joke, Aktas, Bahriye, Forstbauer, Helmut, Grischke, Eva-Maria, Scheffen, Iris, Malter, Wolfram, von Schumann, Raquel, Just, Marianne, Zu Eulenburg, Christine, Biehl, Claudia, Kolberg-Liedtke, Cornelia, Deurloo, Regula, de Haas, Sanne, Jóźwiak, Katarzyna, Hauptmann, Michael, Kates, Ronald, Graeser, Monika, Wuerstlein, Rachel, Kreipe, Hans H, Gluz, Oleg

“…Neoadjuvant chemotherapy is standard of care in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), irrespective of the…”
Get full text

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial by Kolberg-Liedtke, Cornelia, Feuerhake, Friedrich, Garke, Madlen, Christgen, Matthias, Kates, Ronald, Grischke, Eva Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Graeser, Monika, Nitz, Ulrike, Kreipe, Hans, Gluz, Oleg, Harbeck, Nadia

“…Higher density of stromal tumor-infiltrating lymphocytes (sTILs) at baseline has been associated with increased rates of pathological complete response (pCR)…”
Get full text

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study by MOEBUS, Volker, JACKISCH, Christian, HARBECK, Nadia, VON MINCKWITZ, Gunter, RUNNEBAUM, Ingo B, HINKE, Axel, KREIENBERG, Rolf, KONECNY, Gottfried E, UNTCH, Michael, LUECK, Hans-Joachim, DU BOIS, Andreas, THOMSSEN, Christoph, KURBACHER, Christian, KUHN, Walther, NITZ, Ulrike, SCHNEEWEISS, Andreas, HUOBER, Jens

“…Patients with primary breast cancer who have extensive axillary lymph node involvement have a poor prognosis after conventional adjuvant therapy. We compared…”
Get full text

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials by Graeser, Monika, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Herzog, Christopher, Umutlu, Lale, Frydrychowicz, Alex, Rjosk-Dendorfer, Dorothea, Würstlein, Rachel, Culemann, Ralph, Eulenburg, Christine, Adams, Jascha, Nitzsche, Henrik, Prange, Anna, Kümmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Harbeck, Nadia, Kuhl, Christiane K, Nitz, Ulrike

“…Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast…”
Get full text

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial by Gluz, Oleg, Nitz, Ulrike A, Christgen, Matthias, Kuemmel, Sherko, Holtschmidt, Johannes, Schumacher, Johannes, Hartkopf, Andreas, Potenberg, Jochem, Lüedtke-Heckenkamp, Kerstin, Just, Marianne, Schem, Christian, von Schumann, Raquel, Kolberg-Liedtke, Cornelia, Eulenburg, Christine Zu, Schinköthe, Timo, Graeser, Monika, Wuerstlein, Rachel, Kates, Ronald E, Kreipe, Hans Heinrich, Harbeck, Nadia

“…Combination of chemotherapy with (dual) ERBB2 blockade is considered standard in hormone receptor (HR)-positive/ERBB2-positive early breast cancer (EBC)…”
Get more information

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer by Nitz, Ulrike, Gluz, Oleg, Kreipe, Hans H., Christgen, Matthias, Kuemmel, Sherko, Baehner, Frederick L., Shak, Steven, Aktas, Bahriye, Braun, Michael, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Nuding, Benno, Darsow, Maren, Schumacher, Claudia, Krauss, Katja, Malter, Wolfram, Thill, Marc, Warm, Mathias, Wuerstlein, Rachel, Kates, Ronald E., Harbeck, Nadia

“…Background: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently…”
Get full text

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic by Dowsett, Mitch, Ellis, Matthew J., Dixon, J. Michael, Gluz, Oleg, Robertson, John, Kates, Ronald, Suman, Vera J., Turnbull, Arran K., Nitz, Ulrike, Christgen, Matthias, Kreipe, Hans, Kuemmel, Sherko, Bliss, Judith M., Barry, Peter, Johnston, Stephen R., Jacobs, Samuel A., Ma, Cynthia X., Smith, Ian E., Harbeck, Nadia

“…Many patients with ER+ HER2− primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We…”
Get full text

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer by Grote, Isabel, Bartels, Stephan, Kandt, Leonie, Bollmann, Laura, Christgen, Henriette, Gronewold, Malte, Raap, Mieke, Lehmann, Ulrich, Gluz, Oleg, Nitz, Ulrike, Kuemmel, Sherko, Eulenburg, Christine, Braun, Michael, Aktas, Bahriye, Grischke, Eva‐Maria, Schumacher, Claudia, Luedtke‐Heckenkamp, Kerstin, Kates, Ronald, Wuerstlein, Rachel, Graeser, Monika, Harbeck, Nadia, Christgen, Matthias, Kreipe, Hans

“…Background Whereas the genomic landscape of endocrine‐resistant breast cancer has been intensely characterized in previously treated cases with local or…”
Get full text

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials by Graeser, Monika, Harbeck, Nadia, Gluz, Oleg, Würstlein, Rachel, zu Eulenburg, Christine, Schumacher, Claudia, Grischke, Eva-Maria, Forstbauer, Helmut, Dimpfl, Moritz, Braun, Michael, Christgen, Matthias, Kreipe, Hans Heinrich, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Kümmel, Sherko, Nitz, Ulrike

“…We assessed the value of breast ultrasound (US) performed at week 3 and 6 and at the end (EOT) of neoadjuvant therapy (NAT) for prediction of pathologic…”
Get full text

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial by Graeser, Monika, Feuerhake, Friedrich, Gluz, Oleg, Volk, Valery, Hauptmann, Michael, Jozwiak, Katarzyna, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kolberg-Liedtke, Cornelia, Kates, Ronald, Wuerstlein, Rachel, Nitz, Ulrike, Kreipe, Hans Heinrich, Harbeck, Nadia

“…BackgroundThe association of early changes in the immune infiltrate during neoadjuvant chemotherapy (NACT) with pathological complete response (pCR) in…”
Get full text

Y-Box–Binding Protein YB-1 Identifies High-Risk Patients With Primary Breast Cancer Benefiting From Rapidly Cycled Tandem High-Dose Adjuvant Chemotherapy by Gluz, Oleg, Mengele, Karin, Schmitt, Manfred, Kates, Ronald, Diallo-Danebrock, Raihana, Neff, Frauke, Royer, Hans-Dieter, Eckstein, Niels, Mohrmann, Svjetlana, Ting, Evelyn, Kiechle, Marion, Poremba, Christopher, Nitz, Ulrike, Harbeck, Nadia

“…To investigate the potential of Y-box-binding protein YB-1, a multifunctional protein linked to tumor aggressiveness and multidrug resistance, to identify…”
Get full text

Fatal events during clinical trials: an evaluation of deaths during breast cancer studies by Furlanetto, Jenny, von Minckwitz, Gunter, Lederer, Bianca, Möbus, Volker, Schneeweiss, Andreas, Huober, Jens, Fasching, Peter A., Gerber, Bernd, Bauerfeind, Ingo, Nitz, Ulrike, Lück, Hans-Joachim, Hanusch, Claus, Thomssen, Christoph, Untch, Michael, Nekljudova, Valentina, Mehta, Keyur, Loibl, Sibylle

“…Background Information on deaths occurring during oncological clinical trials has never been systematically assessed. Here, we examine the incidence of death…”
Get full text

Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose–Dense Chemotherapy by DIALLO-DANEBROCK, Raihanatou, TING, Evelyn, WILD, Peter J, BURSON, Michael, GABBERT, Helmut E, NITZ, Ulrike, POREMBA, Christopher, GLUZ, Oleg, HERR, Alexander, MOHRMANN, Svjetlana, GEDDERT, Helene, RODY, Achim, SCHAEFER, Karl-Ludwig, BALDUS, Stephan E, HARTMANN, Arndt

“…Purpose: To characterize the prognostic and predictive impact of protein expression profiles in high-risk breast cancer patients who had previously been shown…”
Get full text

High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials by BERRY, Donald A, UENO, Naoto T, BERGH, Jonas, NITZ, Ulrike A, GIANNI, Alessandro M, BASSER, Russell L, ZANDER, Axel R, COOMBES, R. Charles, ROCHE, Henri, TOKUDA, Yutaka, DE VRIES, Elisabeth G. E, HORTOBAGYI, Gabriel N, JOHNSON, Marcella M, CROWN, John P, PEDRAZZOLI, Paolo, BREGNI, Marco, DEMIRER, Taner, XIUDONG LEI, CAPUTO, Jean, RODENHUIS, Sjoerd, PETERS, William P, LEONARD, Robert C, BARLOW, William E, TALLMAN, Martin S

“…Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to…”
Get full text

Randomized Trial of Single Compared With Tandem High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in Patients With Chemotherapy-Sensitive Metastatic Breast Cancer by KRÖGER, Nicolaus, FRICK, Markus, RUFFERT, Ute, HÄNEL, Matthias, BODENSTEIN, Heinrich, NEUBAUER, Andreas, EHNINGER, Gerhard, WOLF, Hans-Heinrich, KOLBE, Kathrin, BUROCK, Karin, ZANDER, Axel R, NITZ, Ulrike, GLUZ, Oleg, MOHRMANN, Svjetlana, METZNER, Bernd, JACKISCH, Christian, KO, Yon, LINDEMANN, Hans-Walter, MEIER, Carl Richard, LOHRMANN, Hans Peter

“…To compare progression-free survival between single and tandem high-dose chemotherapy (HDT) followed by autologous stem-cell transplantation in…”
Get full text

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade by Müller, Philipp, Kreuzaler, Matthias, Khan, Tarik, Thommen, Daniela S, Martin, Kea, Glatz, Katharina, Savic, Spasenija, Harbeck, Nadia, Nitz, Ulrike, Gluz, Oleg, von Bergwelt-Baildon, Michael, Kreipe, Hans, Reddy, Sai, Christgen, Matthias, Zippelius, Alfred

“…Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged as a powerful strategy for cancer…”
Get more information